

---

---

# Bulletin #37

---

---

## Manitoba Drug Benefits and Interchangeability Formulary Amendments



Copies of the consolidated regulations for Pharmacare benefits and interchangeable drugs (including the enclosed amendments), will be available, along with a copy of this bulletin on the Internet on July 22, 2002.

<http://www.gov.mb.ca/health/mbdif>

The following changes will be made to the Pharmacare

benefit list effective  
July 22, 2002.

<b>Inside This Issue</b>	
Part 1 Additions	Page 2
Part 2 Additions & Amendments	Page 3
Part 3	Page 3 & 4
New Interchangeable Categories	Page 4
New Interchangeable Products	Page 5 & 6
Product Deletions	Page 7 & 8
Category Deletions	Page 8
Interchangeable Product Price Changes	Page 8 & 9
Discontinued Products	Page 9
Manufacturers Update	Page 9 & 10
Health Canada Information	Page 10 & 11

**Bulletin 37**  
Effective date July 22, 2002

**Part 1 Additions**

DIN	TRADE NAME	GENERIC	DOSAGE	FORM	MFG* ABB
02244790 02244791 02244792	<b>Alti-Morphine Sulfate SR</b>	morphine sulphate	15 mg 30 mg 60 mg	Tablets	ALT
02243611 02243612	<b>Apo-Alpraz</b>	alprazolam	1 mg 2 mg	Tablets	APX
02243827	<b>Apo-Ipravent</b>	ipratropium bromide	125 mcg/mL	Inhalation Solution Sterules	APX
02243989	<b>Apo-Ketorolac</b>	ketorolac tromethamine	30 mg/mL	Injection	APX
02243828	<b>Apo-Salvent</b>	salbutamol sulfate	0.5 mg/mL	Solution	APX
02205963	<b>Dexiron</b>	iron dextran	50 mg/mL	Injection	LUI
02244462 02244463 02244464 02244465 02244466 02244467	<b>Gen-Warfarin</b>	warfarin sodium	1 mg 2 mg 2.5 mg 4 mg 5 mg 10 mg	Tablets	GPM
02221780	<b>Infufer</b>	iron dextran	50 mg/mL	Injection	SAB
01916386	<b>pms-Hydromorphone</b>	hydromorphone HCl	1mg/mL	Syrup	PMS
02245101 02245102 02245103 02245111	<b>pms-Nefazodone</b>	nefazodone HCl	50 mg 100 mg 150 mg 200 mg	Tablets	PMS
02244838 02244839 02244840	<b>pms-Sertraline</b>	sertraline HCl	25 mg 50 mg 100 mg	Capsules	PMS
02245159 02245160 02245161	<b>Rhoxal-Sertraline</b>	sertraline HCl	25 mg 50 mg 100 mg	Capsules	RXP

\* Abbreviation of Manufacturer' Names

**Part 2 Additions and Amendments**

- The criteria for **Plavix** has been revised as follows:  
Plavix will be reimbursed for patients:
  - a) For secondary prevention of vascular ischemic events ie: myocardial infarction or stroke
    - i. who are known to be or become intolerant to ASA or ticlopidine, or
    - ii. who continue to have TIA or stroke symptoms or myocardial infarction while being treated with ASA or ticlopidine.

NOTE: ASA should be first line for the secondary prevention of vascular ischemic events such as myocardial infarction or stroke. Before abandoning ASA, efforts should be made to improve tolerability of ASA by reducing the dose, taking it with food and using enteric coated ASA.

- b) Post coronary stent implantation x 28 days **alone or** in combination with ASA.
- c) Acute coronary syndromes (ACS) **alone or in combination with ASA** for a maximum of 6 months.

NOTE: Acute coronary syndromes (ACS) include unstable angina and non ST - elevation MI.

**Part 3**

**The following products will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis:**

<b>Rhoxal-Nabumetone</b>	nabumetone	500 mg	Tablets	RXP
--------------------------	------------	--------	---------	-----

- Where at least two other non-steroidal anti-inflammatory drugs (NSAIDs) have been tried and failed or were not tolerated.

**Bulletin 37**  
Effective date July 22, 2002

<b>Rhoxal-Oxaprozin</b>	oxaprozin	600 mg	Tablets	RXP
-------------------------	-----------	--------	---------	-----

- Where at least two other non-steroidal anti-inflammatory drugs (NSAIDs) have been tried and failed or were not tolerated.

**New Interchangeable Categories**

**The following new interchangeable categories and products were added:**

• Generic Name			
DIN	Trade Name	Manufacturer	Price in Cents

• Dibucaine HCl/Esculin/Framycetin Sulfate/Hydrocortisone - 5 mg/10 mg/10 mg/5 mg - Ointment			
01988549	Proctosedyl	AVE	93.14
02242527	sab-Proctomyxin HC	SIL	65.56

• Dibucaine HCl/Esculin/Framycetin Sulfate/Hydrocortisone - 5 mg/10 mg/10 mg/5 mg - Suppositories			
02223260	Proctosedyl	AVE	108.17
02242528	sab-Proctomyxin HC	SIL	87.18

• Hydromorphone HCl - 1 mg/mL - Oral Liquid			
00786535	Dilaudid	ABB	8.71
01916386	pms-Hydromorphone	PMS	8.71

• Morphine Sulfate - 15 mg - Sustained Release Tablets			
02015439	MS Contin SRT	PFR	65.50
02244790	Alti-Morphine Sulfate SR	ALT	45.85

• Morphine Sulfate - 30 mg - Sustained Release Tablets			
02014297	MS Contin SRT	PFR	98.89
02244791	Alti-Morphine Sulfate SR	ALT	69.22

• Morphine Sulfate - 60 mg - Sustained Release Tablets			
02014300	MS Contin SRT	PFR	174.33
02244792	Alti-Morphine Sulfate SR	ALT	122.03

**New Interchangeable Products**

The following products have been added to existing interchangeable drug categories:

			Price in Cents
<b>• Alprazolam - 1 mg - Tablets</b>			
02243611	Apo-Alpraz	APX	34.09
<b>• Alprazolam - 2 mg - Tablets</b>			
02243612	Apo-Alpraz	APX	60.59
<b>• Ipratropium Bromide - 125 mcg/mL - Unit Dose Vial</b>			
02243827	Apo-Ipravent	APX	**37.75
<b>• Ketorolac Tromethamine - 30 mg/mL - Injection</b>			
02243989	Apo-Ketorolac	APX	**386.00
<b>• Nabumetone - 500 mg - Tablets</b>			
02242912	Rhoxal-Nabumetone	RXP	55.28
<b>• Nefazodone HCl - 50 mg - Tablets</b>			
02245101	pms-Nefazodone	PMS	56.47
<b>• Nefazodone HCl - 100 mg - Tablets</b>			
02245102	pms-Nefazodone	PMS	61.60
<b>• Nefazodone HCl - 150 mg - Tablets</b>			
02245103	pms-Nefazodone	PMS	61.60
<b>• Nefazodone HCl - 200 mg - Tablets</b>			
02245111	pms-Nefazodone	PMS	71.87
<b>• Oxaprozin - 600 mg - Tablets</b>			
02243799	Rhoxal-Oxaprozin	RXP	57.20

**Bulletin 37**  
Effective date July 22, 2002

• Salbutamol Sulfate - 1.25 mg/2.5 mL - Unit Dose Solution Nebules			
02243828	Apo-Salvent	APX	16.40
• Sertraline HCl - 25 mg - Capsules			
02244838	pms-Sertraline	PMS	55.44
02245159	Rhoxal-Sertraline	RXP	55.44
• Sertraline HCl - 50 mg - Capsules			
02244839	pms-Sertraline	PMS	110.88
02245160	Rhoxal-Sertraline	RXP	110.88
• Sertraline HCl - 100 mg - Capsules			
02244840	pms-Sertraline	PMS	121.28
02245161	Rhoxal-Sertraline	RXP	121.28
• Warfarin Sodium - 1 mg - Tablets			
02244462	Gen-Warfarin	GPM	21.78
• Warfarin Sodium - 2 mg - Tablets			
02244463	Gen-Warfarin	GPM	23.04
• Warfarin Sodium - 2.5 mg - Tablets			
02244464	Gen-Warfarin	GPM	**18.44
• Warfarin Sodium - 4 mg - Tablets			
02244465	Gen-Warfarin	GPM	28.56
• Warfarin Sodium - 5 mg - Tablets			
02244466	Gen-Warfarin	GPM	18.48
• Warfarin Sodium - 10 mg - Tablets			
02244467	Gen-Warfarin	GPM	33.16

**\*\* The price change has resulted in a change to the lowest price in the category.**  
**() Denotes the price of the lowest generic product in the product category.**

**Bulletin 37**  
Effective date July 22, 2002

**Product Deletions**

The following products have been deleted (notification was provided in Bulletin 36).

02041316	Amoxil	amoxicillin	125 mg/5 mL	Oral Liquid
02042592	Amoxil	amoxicillin	250 mg/5 mL	Oral Liquid
02169894	Asendin	amoxapine	50 mg	Tablets
00714488	Bisacolax	bisacodyl	5 mg	Enteric Tablets
00714917	Flamazine C	chlorhexidine gluconate silver sulfadiazine	2 mg/10 mg/gm	Cream
01979914	Hydromorphone HCl	hydromorphone HCl	3 mg	Suppositories
02228343	Loperacap	loperamide	2 mg	Tablets
02170663	Methotrexate Sodium	methotrexate	50 mg/2 mL	Liquid
00855820	Motilium	domperidone maleate	10 mg	Tablets
02238076	Phospholine Iodide	echothiophate iodide	6.25 mg/5 mL	Powder for Solution
02043556	Reglan	metoclopramide HCl	5 mg/mL	Injection
02043505	Quinidex Extentabs	quinidine sulfate	300 mg	Slow Release Tablets
02043688	Serax	oxazepam	30 mg	Tablets
02242914	Taro-Etodolac	etodolac	200 mg	Capsules
02242915	Taro-Etodolac	etodolac	300 mg	Capsules

The following products have been deleted:

01940120	<b>Aquacort</b>	hydrocortisone	2.5%	Topical Lotion
00391077	<b>Corium</b>	chlordiazepoxide HCl - clidinium Br	5 mg - 2.5 mg	Capsules (20.20)
00016446	<b>Cortone</b>	cortisone acetate	25 mg	Tablets
00213624	<b>Decadron Phosphate</b>	dexamethasone sodium phosphate	4 mg/mL	Injection
00016322	<b>Elavil</b>	amitriptyline HCl	10 mg	Tablets
00016330	<b>Elavil</b>	amitriptyline HCl	25 mg	Tablets
00717517	<b>Nu-Medopa</b>	methyldopa	125 mg	Tablets
00717509	<b>Nu-Medopa</b>	methyldopa	250 mg	Tablets

**Bulletin 37**  
Effective date July 22, 2002

00717576	<b>Nu-Medopa</b>	methyldopa	500 mg	Tablets
02244474	<b>pms-Clobazam</b>	clobazam	10 mg	Tablets
02043661	<b>Serax</b>	oxazepam	15 mg	Tablets
00349720	<b>Urecholine</b>	bethanechol chloride	10 mg	Tablets
00349739	<b>Urecholine</b>	bethanechol chloride	25 mg	Tablets

**Category Deletions**

The following categories have been deleted:

- Amitriptyline HCl - 10 mg - Tablets
- Amitriptyline HCl - 25 mg - Tablets
- Bethanechol Chloride - 10 mg - Tablets
- Bethanechol Chloride - 25 mg - Tablets
- Cortisone Acetate - 25 mg - Tablets
- Dexamethasone Sodium Phosphate - 4 mg/mL - Injection
- Hydrocortisone - 2.5% - Topical Lotion
- Methyldopa - 125 mg - Tablets
- Methyldopa - 500 mg - Tablets
- Oxazepam - 15 mg - Tablets
- Oxazepam - 30 mg - Tablets

**Interchangeable Product Price Changes**

The following changes in prices have occurred:

00621447	Anuzinc	zinc sulfate monohydrate	0.5%	Topical Ointment	**10.27
Old din 01987534 New din 02224550	Diabeta	glyburide	2.5 mg	Tablets	11.59
02243588	Gen-Nitro	nitroglycerin	0.4 mg/dose	Spray	**4.99
00653233	Lenoltec No. 1	acetaminophen compound with codeine	8 mg	Tablets	3.03
00643025	Noroxin	norfloxacin	400 mg	Tablets	217.94
01926284	Surmontil	trimipramine	100 mg	Tablets	107.38



**Bulletin 37**  
Effective date July 22, 2002

02166712	sab-Timolol	timolol maleate	0.25%	Ophthalmic Solution	155.00
02166720	sab-Timolol	timolol maleate	0.5%	Ophthalmic Solution	186.00

**\*\*The price change has resulted in a change to the lowest price in the category.**

**() Denotes the price of the lowest generic product in the product category.**

**Discontinued Products**

**Notice has been received from the manufacturer that the following products have been discontinued. They will be deleted with the next Formulary amendments.**

00016306	Elavil Pamoate	amitriptyline pamoate	10 mg/5 mL	Syrup
00782742	Flexeril	cyclobenzaprine HCl	10 mg	Tablets
00016500	Hydrodiuril	hydrochlorothiazide	25 mg	Tablets
00534609	Intal	sodium cromoglycate	1%	Nebulizer Solution
02170027	Loxapac	loxapine succinate	10 mg	Tablets
02170132	Loxapac	loxapine succinate	25 mg	Tablets
02170078	Myambutol	ethambutol HCl	400 mg	Tablets
01908294	Noroxin	norfloxacin	0.3%	Ophthalmic Solution
02230362	Norventyl	nortriptyline	25 mg	Capsules
02043521	Reglan	metoclopramide HCl	400 mg	Tablets
01989782	Surgam	tiaprofenic acid	200 mg	Tablets
00364126	Tolectin	tolectin sodium	200 mg	Tablets
00484938	Tolectin	tolectin sodium	400 mg	Capsules
00632740	Tolectin	tolectin sodium	600 mg	Tablets
02142023	Ultradol	etodolac	200 mg	Capsules

**Manufacturer Updates**

**Please note that the following pre-filled syringe will replace Copaxone 20 mg vial - DIN 02233014**

02245619	Copaxone	glatiramer acetate	20 mg/1.0 mL	Pre-filled syringe kit
----------	----------	--------------------	--------------	------------------------

**Bulletin 37**  
Effective date July 22, 2002

The following products have a DIN change and a change in manufacturer designation:

Old DIN	New DIN	Current Brand	Generic	Manufacturer
01987534	02224550	Diabeta	glyburide	AVE
01987836	02224569	Diabeta	glyburide	AVE
01989774	02221950	Surgam	tiaprofenic acid	AVE

**Please note that the new distributor for Prestige Blood Glucose Strips is Thermor Ltd. This product was previously listed under the Canadian distributor MOG-Med-O-Gen Medical Inc.**

**NOTE:**

Effective May 9, 2002, the requirement for folic acid testing for initial Part 3 coverage of cholinesterase inhibitors, Aricept, Exelon and Reminyl, is no longer required. Manitoba Health recognizes that folic acid testing is no longer routinely done therefore testing of folic acid is no longer a requirement.

**HEALTH CANADA INFORMATION**

- On January 14, 2002, Novartis Pharma Canada Inc., the manufacturer of Clozaril (clozapine), sent a "Dear Healthcare Professional" letter to healthcare workers to warn of cardiovascular toxicity.
- On March 6, 2002, Bristol-Myers Squibb, the manufacturer of Zerit (stavudine, d4T) sent a "Dear Healthcare Professional" letter to healthcare workers to explain concern about rare occurrences of rapidly ascending neuromuscular weakness, mimicking the clinical presentation of Guillain-Barré syndrome (including respiratory failure), in HIV-infected patients receiving Zerit in combination with other antiretrovirals.

**Bulletin 37**  
**Effective date July 22, 2002**

- On April 19, 2002, Merck Frosst Canada Ltd., the manufacturer of Vioxx (rofecoxib), sent a “Dear Healthcare Professional” letter to healthcare workers to warn of safety information related to the selective COX-2 inhibitor Vioxx.
- On May 13, 2002, Pharmacia Canada Inc and Pfizer Canada Inc., the manufacturers of Celebrex sent a “Dear Healthcare Professional” letter to healthcare workers to warn of safety information related to the selective COX-2 inhibitor Celebrex.
- On May 14, 2002, Wyeth-Ayerst Canada Inc., the manufacturer of Rapamune (sirolimus), sent a “Dear Healthcare Professional” letter to healthcare workers to warn that the safety and efficacy of Rapamune as immunosuppressive therapy have not been established in liver transplant patients, and therefore, such use is not recommended.
- The above information can be accessed on the Internet at:

[http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/adviss\\_ind\\_e.html](http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/adviss_ind_e.html)